Lara Longpre - Jan 31, 2023 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
Chief Development Officer
Signature
/s/ Jody Howe, Attorney-in-Fact
Stock symbol
MIRM
Transactions as of
Jan 31, 2023
Transactions value $
$0
Form type
4
Date filed
2/2/2023, 04:46 PM
Previous filing
Nov 14, 2022
Next filing
May 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Award $0 +9.63K +9.97% $0.00 106K Jan 31, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Stock Option (right to buy) Award $0 +38.5K $0.00 38.5K Jan 31, 2023 Common Stock 38.5K $23.48 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan.
F2 1/4th of the shares vest one year after January 31, 2023 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.